Literature DB >> 6792284

Polyethylene glycol enhances the binding of C1q to circulating immune complexes.

C E Hack, A J Eerenberg-Belmer, A J Hannema, T A Out, R C Aalberse.   

Abstract

By radioimmunoassay we measured the amount of endogenous C1q that was precipitated by polyethylene glycol (PEG) under the conditions of the 125I-C1q-binding test (C1q-BT). We found a linear correlation between the percentage endogenous C1q that was precipitated and the 125I-C1q-binding activity (C1q-BA). We concluded that the 125I-C1q behaves like the endogenous C1q. To detect circulating immune complexes (CIC) which had already bound C1q, human sera were added to tubes coated with anti-C1q. Under the conditions used, no C1q-bearing CIC were detected. In addition, 7 sera from patients with high C1q-BA were analyzed by sucrose-gradient ultracentrifugation. No C1q was found in the fast sedimenting fractions, although C1q-BA was detected in these fractions. With IgG-coated tubes we observed that PEG enhanced the binding of 125I-C1q as well as endogenous C1q to aggregated and monomeric IgG. PEG also enhanced the binding of CIC to C1q-coated tubes. The results suggest that CIC detected by the C1q-BT do not bear C1q in significant amounts in the circulation and that these CIC become detectable only in the presence of PEG.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6792284     DOI: 10.1016/0022-1759(81)90349-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Immunoglobulin inclusions in rheumatoid arthritis polymorphonuclear cells: lack of correlation with circulating immune complexes.

Authors:  D H Goddard; K A Brown; A P Kirk; D McCarthy; G D Johnson; E J Holborow
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

2.  Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.

Authors:  A P van Dam; C E Hack
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

3.  Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.

Authors:  A J Swaak; A Hannema; C Vogelaar; F A Boom; L van Es; R van Aalst; L W Statius van Eps
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

4.  Anti-C1q affinity isolated circulating immune complexes correlate with extra-articular rheumatoid disease.

Authors:  R D Melsom; A C Horsfall; L Schrieber; P Charles; R N Maini
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  SLE like syndrome and functional deficiency of C1q in members of a large family.

Authors:  A J Hannema; J C Kluin-Nelemans; C E Hack; A J Eerenberg-Belmer; C Mallée; H P van Helden
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

6.  Biosynthesis of normal and low-molecular-mass complement component C1q by cultured human monocytes and macrophages.

Authors:  R Hoekzema; M C Brouwer; E R de Graeff-Meeder; H P van Helden; C E Hack
Journal:  Biochem J       Date:  1989-01-15       Impact factor: 3.857

7.  Immunisation of guinea-pigs with circulating immune complexes from patients with rheumatoid arthritis.

Authors:  C E Hack; H G Lim; R C Aalberse
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.